#United States #New York #Pomerantz Law #Investor Alert #LENZ Therapeutics

Investor Alert: Investigation Launched into LENZ Therapeutics, Inc.

Pomerantz LLP, a prominent law firm recognized for its expertise in class action litigation, has initiated an investigation into potential claims affecting the investors of LENZ Therapeutics, Inc. This inquiry is centered on allegations of securities fraud or other unlawful business practices allegedly carried out by the company and some of its senior executives.

The investigation was prompted following the company's recent financial disclosures, which revealed disparities in their reported revenues. On August 11, 2026, LENZ announced its second-quarter revenue figures, which totaled $5.5 million. However, a substantial portion of this revenue—approximately $3.8 million—was derived from one-time, non-recurring global licensing milestones. This raises questions concerning the sustainability and efficacy of the company’s core products, particularly the commercial eye drop VIZZ.

The reported organic sales of VIZZ were disappointing, amounting to just $1.73 million, indicating a mere 9% growth in volume compared to the previous quarter. In light of this underwhelming performance, Bank of America promptly downgraded the stock rating for LENZ from 'Buy' to 'Neutral', while simultaneously slashing the price target from $31.00 to $7.00. This was attributed to a far slower-than-anticipated commercial launch of VIZZ, which notably affected investor confidence and subsequently resulted in a significant drop in the company's stock price, ultimately harming its investors.

Pomerantz LLP is reaching out to affected investors to gather insights and assess their potential legal claims. Danielle Peyton, an attorney at Pomerantz, is leading the communication efforts, urging investors to come forward to discuss their experiences. Interested parties can reach out via email or call the firm for further information on joining the ongoing class action.

Founded by Abraham L. Pomerantz, recognized as a pioneer in securities class actions, Pomerantz has, for over 85 years, persistently advocated for the rights of investors who have suffered from breaches of fiduciary duty and corporate misconduct. The firm has a successful track record, having secured substantial damages for its clients in past cases.

As this investigation unfolds, investors are advised to stay vigilant and consider their options, as Pomerantz LLP prepares to take the necessary legal steps against any potential wrongdoing by LENZ Therapeutics, Inc. The firm's commitment to securing justice for harmed parties remains firm, and their investigators are diligently gathering further evidence to support affected investors in their quest for compensation.

For those who may have been impacted, reaching out to Pomerantz LLP is highly advisable. They are aware of the emotional and financial distress that often accompanies securities fraud, and they are determined to assist investors in navigating this complex legal landscape.

For more information or to connect with Pomerantz LLP, you can contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.